Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (189 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 49 | 2,468 | 44% |
| 2020 | 37 | 2,200 | 47% |
| 2021 | 38 | 2,262 | 51% |
| 2022 | 43 | 2,350 | 54% |
| 2023 | 38 | 2,349 | 57% |
| 2024 | 41 | 2,404 | 59% |
| 2025 from claims | – | 2,681 2,455–2,845 | 59% |
| 2026 forecast | – | 2,794 2,459–3,212 | 60% |
| 2027 forecast | – | 2,910 2,489–3,451 | 60% |
| 2028 forecast | – | 3,029 2,529–3,688 | 61% |
| 2029 forecast | – | 3,153 2,577–3,930 | 61% |
| 2030 forecast | – | 3,282 2,631–4,177 | 62% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 49% of the cases CMS names in Texas; 27 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 30% inpatient hospital, 70% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~2,800 | ~810 | ~2,000 |
| 2027 · ~2,900 | ~820 | ~2,100 |
| 2028 · ~3,000 | ~840 | ~2,200 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 28% (30% in 2025), hospital outpatient about 72% (70% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 36 | 2,306+0.2%/yr | +0.2%/yr | 1.1 | 0% | 2,680 in 2030+2.5%/yr |
| North Carolina | 14 | 1,012−3%/yr | −3%/yr | 1.1 | 0% | 1,160 in 2030+2.3%/yr |
| Tennessee | 17 | 950−5%/yr | −5%/yr | 1.5 | 0% | 1,060 in 2030+1.8%/yr |
| Georgia | 20 | 915−0.7%/yr | −0.7%/yr | 1.2 | 0% | 960 in 2030+0.8%/yr |
| Virginia | 21 | 880−2%/yr | −2%/yr | 0.9 | 0% | 1,030 in 2030+2.6%/yr |
| Maryland | 15 | 785−2.3%/yr | −2.3%/yr | 0.9 | 0% | 910 in 2030+2.5%/yr |
| South Carolina | 12 | 678+1.8%/yr | +1.8%/yr | 1.1 | 0% | 1,120 in 2030+8.7%/yr |
| Oklahoma | 10 | 547−0.4%/yr | −0.4%/yr | 1.2 | 0% | 600 in 2030+1.5%/yr |
| Louisiana | 4 | 436−2.2%/yr | −2.2%/yr | 1.2 | 0% | 460 in 2030+1%/yr |
| Alabama | 5 | 408−7.8%/yr | −7.8%/yr | 1.0 | 0% | 380 in 2030−1.2%/yr |
| Arkansas | 7 | 373−2.3%/yr | −2.3%/yr | 1.1 | 0% | 450 in 2030+3.3%/yr |
| Kentucky | 5 | 339−1.5%/yr | −1.5%/yr | 0.8 | 0% | 370 in 2030+1.4%/yr |
| Mississippi | 9 | 334−6%/yr | −6%/yr | 1.0 | 0% | 280 in 2030−2.7%/yr |
| District of Columbia | 8 | 257+5.7%/yr | +5.7%/yr | 4.4 | 0% | 360 in 2030+5.7%/yr |
| West Virginia | 1 | 118+1.6%/yr | +1.6%/yr | 0.6 | 0% | 220 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 150 | 9,781−6.5%/yr | −6.5%/yr | 4.50.9× | 41% | 9,730 in 2030−0.1%/yr |
| Kidney stone management | 182 | 8,871−1.5%/yr | −1.5%/yr | 4.20.8× | 17% | 10,800 in 2030+3.3%/yr |
| Incontinence, prolapse & sacral neuromodulation | 85 | 5,993−0.2%/yr | −0.2%/yr | 2.81.1× | 24% | 8,350 in 2030+5.7%/yr |
| Hysterectomy, hysteroscopy & ablation | 48 | 4,404−1.1%/yr | −1.1%/yr | 2.30.9× | 16% | 5,010 in 2030+2.2%/yr |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Intuitive Surgical leads with 97% of company spending on these surgeons in 2025, level with 2024.
In 2025, 3 companies reported engagement with Texas’s surgeons worth $668K in consulting, speaking, meals and travel tied to these products, about $16K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.